Hi Dr T@Davisite
Given the funded P1A/B clinical trial will encompass all solid tumours, including Lung Cancer, will this supersede the former Lung Cancer trial whose details and progress that was never fully revealed to shareholders presumably due to legal issues with CoH or some other party?
Are you in a position to enlighten us on this pathway or is still tied up in legal red tape?
Second unrelated question is if RACE were hypothetically able to develop an oral version of Bisantrene, is that similarly treated as a new drug with the same approval/safety/toxicology pathway approvals as RC220 is now going through with the added benefit of improved patient utility & resetting patent life?
Ann: Updated Strategy and Investor Presentation, page-370
-
- There are more pages in this discussion • 139 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.62 |
Change
0.015(0.93%) |
Mkt cap ! $272.6M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.55 | $456.1K | 284.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3324 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2660 | 1 |
View Market Depth
| Last trade - 15.58pm 30/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |